Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01724346 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 3
- Development phase
- 269
- Enrollment target
NCT01724346 is a Phase 3 study that has completed, run by Pharmacyclics. The registered enrollment target is 269 participants.
The verdict
NCT01724346, a Phase 3 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 269 participants
- Enrollment target
Study Summary
An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib versus Chlorambucil)
Interventions
- DRUG Ibrutinib
- DRUG Next-line ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2013-12-03 |
| Est. Completion | 2023-08-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01724346
The ClinicalTrials.gov registry entry for NCT01724346 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 269 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ibrutinib is the first listed.
NCT01724346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01724346 about?
NCT01724346 is a clinical study titled "Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib versus Chlorambucil)
What is the current status of trial NCT01724346?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 269 participants. The study started on 2013-12-03. Estimated completion is 2023-08-18.
What interventions are being tested in trial NCT01724346?
The interventions under investigation include: Ibrutinib (DRUG), Next-line ibrutinib (DRUG).
Who is sponsoring clinical trial NCT01724346?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.